CLYM vs ZVRA: stock comparison and AI forecast
Climb Bio, Inc. (CLYM) and Zevra Therapeutics, Inc. (ZVRA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CLYM Climb Bio, Inc.
- Price
- $10.29 -13.6% · 6M
- Market Cap
- $591M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
ZVRA Zevra Therapeutics, Inc.
- Market Cap
- $625M
- P/E Ratio
- 25.7x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- CLYM and ZVRA have similar market capitalizations ($591M and $625M).
- ZVRA carries 0.31 times debt per unit of equity, against 0.04 times for CLYM.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CLYM | ZVRA |
|---|---|---|
| Market Cap | $591M | $625M |
| P/E Ratio | – | 25.68x |
| P/B Ratio | 2.59x | 2.62x |
| EPS | $-0.87 | $0.41 |
| Book Value/Share | $3.97 | $4.02 |
| Revenue/Share | – | $2.49 |
| FCF/Share | – | $0.64 |
Profitability & Margins
| Metric | CLYM | ZVRA |
|---|---|---|
| ROE | -26.0% | – |
| ROA | -25.1% | – |
| ROIC | -29.2% | 33.0% |
| Gross Margin | – | 94.5% |
| Operating Margin | – | 60.8% |
| EBT Margin | – | 60.9% |
| Tax Rate | 0.0% | 13.3% |
Financial Health
| Metric | CLYM | ZVRA |
|---|---|---|
| Current Ratio | 26.58x | 5.46x |
| Quick Ratio | – | 5.38x |
| D/E Ratio | 0.04x | 0.31x |
| Financial Leverage | 1.04x | 1.31x |
| Interest Coverage | – | 8.4x |
| Working Capital | $202M | $184M |
Cash Flow
| Metric | CLYM | ZVRA |
|---|---|---|
| Operating Cash Flow | -$53M | $39M |
| Free Cash Flow | – | $38M |
| Capital Spending | – | -$460K |
| FCF/Sales | – | 25.9% |
| CapEx/Sales | – | 0.3% |
Operational Efficiency
| Metric | CLYM | ZVRA |
|---|---|---|
| Asset Turnover | – | 0.47x |
| Inventory Turnover | – | 2.6x |
| Fixed Assets Turnover | – | 181.1x |
| Days Inventory | – | 139 days |
| Payables Period | – | 618 days |
Income Statement
| Metric | CLYM | ZVRA |
|---|---|---|
| Total Revenue | – | $148M |
| Operating Income | -$67M | $90M |
| Net Income | -$59M | – |
| R&D Expense | $44M | $16M |
| SG&A Expense | – | $77M |
| Cost of Goods Sold | – | $8M |
Dividend & Shareholder Information
| Metric | CLYM | ZVRA |
|---|---|---|
| Shares Outstanding | 57M | 59M |
| EPS Growth | -495.4% | – |
CLYM vs ZVRA: stock comparison and AI forecast
Which is bigger, CLYM or ZVRA?
CLYM and ZVRA have similar market capitalizations ($591M and $625M).
Which one does Intratio's AI model rank higher, CLYM or ZVRA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.